Our Executive Team
Deborah Waterhouse was appointed to GSK’s Corporate Executive Team on 8th January 2020. She became Chief Executive Officer of ViiV Healthcare on 1st April 2018. ViiV Healthcare is majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders.
Deborah joined GSK in 1996 and was most recently the Senior Vice President of Primary Care within the company’s US business, prior to which she led the US Vaccines business.
She brings a wealth of experience to GSK having lived and worked in Europe, Asia Pacific and the USA, and a strong track record of performance in both specialty and primary care. Deborah led the HIV business in the UK before heading the HIV Centre of Excellence for Pharma Europe, and held international roles as General Manager of Australia and New Zealand and Senior Vice President for Central and Eastern Europe.
Jill Anderson became our Chief Financial Officer on 1 August 2018.
Jill joined the ViiV Executive Team from GSK where she was VP Franchise Finance, Global Pharmaceutical and brings more than 25 years of experience working in the industry. She has held a broad range of roles of increasing responsibility across Finance, Commercial, R&D and Manufacturing. In her most recent role, Jill was accountable for leading the finance partnering on global commercial strategy, R&D financial investment appraisal, long range sales planning and profit optimisation across the portfolio lifecycle.
At the beginning of her career, Jill received her accounting qualification at Shell International Petroleum Company. She holds a degree in Chemistry from the University of Exeter, has been a school governor and is an active sponsor of the Accelerating Difference diversity programme in GSK.
Lynn Baxter became our Head of North America on 1 February 2019, joining ViiV Healthcare from GSK where she most recently led the Global Vaccines Commercial business. She has a proven track record of delivering consistent strong performance and impact while in varied roles, geographies, and therapeutic areas.
Prior to this, Lynn held various positions in GSK. She was General Manager of GSK Philippines where she was accountable for running all aspects of the local Pharma operating company. Before moving to the Philippines, she was Head of Commercial Operations for Emerging Markets, based at GSK Global Headquarters in London. Covering more than 100 diverse countries, Lynn was responsible for driving pharmaceuticals business performance, delivering business transformation, and significant global corporate change initiatives, as well as building commercial capabilities.
Previously, Lynn was Global Head of Hepatitis and Travel Vaccines, GSK Global Vaccines based in Belgium where she lead a vertical end-to-end cross-functional matrix organization, encompassing R&D, manufacturing, and commercialization. Earlier on, she was based in Shanghai as Growth Strategy Director for Vaccines. She joined GSK in 2009 as a Marketing Director for Europe and Emerging Markets.
Before joining GSK, Lynn was with Roche Pharmaceuticals in various positions, including HIV Franchise Leader and Global Marketing Excellence Lead. Her earlier career was spent at Merck Sharp & Dohme (MSD) in the UK, in a variety of sales and marketing roles of increasing seniority.
Jocelyn Brown is our global Head of HR and joined ViiV Healthcare from GSK in 2016.
Jocelyn developed her career at GSK since 2002, where she held various HR positions of increasing seniority working in UK Pharma, Consumer Healthcare, GMS, and the HR Talent and Leadership Centre of Excellence. In her most recent role prior to joining ViiV Healthcare Jocelyn supported several GSK Corporate Executive Team members and their leadership teams to deliver change, capability building and talent programmes across the Global Ethics and Compliance and Communications and Government Affairs functions, as well as Global Corporate Development, Corporate Secretariat and the Office of the CEO.
Jocelyn is responsible for delivering HR strategy across ViiV Healthcare, supporting leaders and employees to continue guiding the business through a continued period of growth, develop capability and talent underpinned by our company’s unique culture.
Jocelyn holds a degree in History & Management Studies from the University of Glasgow, Scotland.
Currently lead for the ViiV Healthcare Discovery organisation, Mark Cockett is responsible for delivering new HIV drug candidates that are aligned to future medical needs into clinical development; and providing research support for clinical development assets as they progress in the clinic.
Mark joined ViiV Healthcare in February this year with the acquisition of Bristol-Myers Squibb (BMS) HIV pipeline assets. Previously Mark was VP of Discovery Infectious Diseases at BMS (2008-2016), responsible for delivery of antiviral therapeutics into the pipeline. His team at BMS has delivered marketed products targeting HIV, HBV and HCV as well as the pipeline of HIV drugs recently acquired by ViiV Healthcare. Prior to this at BMS Mark was VP, Applied Genomics (2003-2008) and Executive Director, Functional Genomics (2000-2003) and in those roles led a team that supported all therapeutic areas with genomics technologies and bioinformatics.
Before joining BMS, Mark worked for 7 years in the Neuroscience group at Wyeth, ultimately as Director, molecular & cell biology, and for 10 years in the biotech industry for Celltech PLC, where he worked on mammalian gene expression technology and in oncology. Whilst at Celltech he obtained his Ph.D. in collaboration with the Strangeway Research Laboratory, Cambridge, UK working on the involvement of matrix metalloproteinases in tumour cell invasion.
Mark has published over 50 peer reviewed articles in the field of recombinant gene expression in mammalian cells; the biochemistry and function of several matrix metalloproteinase enzymes and their role in disease; in the field of heterotrimeric G protein signaling; Genomics in the pharmaceutical industry and most recently several virology publications.
Aggie Gallagher is Vice President, Head of ViiV Healthcare Legal and Compliance and joined the ViiV Healthcare Executive Team (VET) on 24th April 2017.
Aggie joined GSK in 2013 as Assistant General Counsel providing strategic legal leadership to Global Vaccines Commercial Global Government Affairs, Public Policy, Patient Advocacy and Communications. She then led the Novartis integration for Vaccines before she was promoted to Vice President, Ethics and Compliance Officer, Vaccines in 2015 to head up risk management and compliance for Vaccines as a member of the Vaccines Executive Team. Prior to joining GSK Aggie held senior Legal roles at Pfizer, Sandoz and Medtronic.
Dr Harmony Garges is our Chief Medical Officer. She is responsible for Regulatory, Safety and Medical Affairs. In 2005, Harmony joined the Infectious Diseases group at GSK and spent several years working on global development programs, as project physician leader for Fosamprenavir, Valtrex and Altabax, leading to three successful NDA/MAA files for new or expanded indications. Harmony provided medical leadership and strategy for the development of various other anti-infectives through phases I to III, including the FTIH dolutegravir trial.
She then joined Global Clinical Safety & Pharmacovigilance, where she provided safety strategy and governance for several large global clinical development programs in Pharma, and as Global VP of the Mature Products Safety Group, with accountability for the safety of over 500 marketed products across the Pharma and Consumer Healthcare (CH) portfolio. Harmony spent three years as the Chief Medical Officer for GSK's Consumer Healthcare business, where she was accountable for all aspects of product safety and medical governance for the global portfolio, and led the medical organisation though the complex JV integration with Novartis.
Harmony graduated with high honors from Colgate University with a degree in Chemistry. She obtained her MD degree and completed her pediatrics residency at Duke University. Following a year as Chief Resident, she completed pediatric infectious diseases and Medical Microbiology fellowships at Duke, along with her MPH in Epidemiology from the University of North Carolina at Chapel Hill.
Harmony is board-certified in General Pediatrics, Medical Microbiology and Pediatrics Infectious Diseases. Harmony is Adjunct Faculty at Duke, where she continues to provide patient care in the Duke Pediatric HIV/ clinic.
Cheryl MacDiarmid is a member of the senior executive team in the US for GSK, a leading, multinational global pharmaceutical company. She is directly responsible for the US primary care sales division; strategy, planning and operations; and marketing, leading more than 2500 employees. A dynamic and strategic general manager, Cheryl brings 20 years of deep experience in building businesses in the US and Canada across sales, marketing and managed markets in both pharmaceuticals and vaccines.
She has a gift for creating and leading extraordinarily powerful teams. She seeks out and thrives on challenge, leading her teams to set an ambition, make choices and execute bold, game-changing moves that pivot and change a business trajectory. Notable recent accomplishments include catalyzing a significant turnaround within the US sales organization while solidifying a path to sustained growth and launching a new type 2 diabetes medicine in the US, exceeding external benchmarks and market expectations.
She is a values-driven leader with significant experience managing commercial risk, compliance and alliance governance. As a pharmacist, Cheryl navigates complex scientific and clinical data with ease and has a passion for respiratory disease and diabetes. She brings a global mindset to her work, having served as a chief of staff associate to the GSK President, International Region.
A native of Canada, Cheryl graduated from the University of Toronto with a degree in Pharmacy and subsequently received an MBA from the Schulich School of Business. She lives in Philadelphia. Her personal passions include running, skiing, and visits north to Canada.
Stephen Rea is Head of External Affairs and Communications.
Stephen started his career at GSK in 2005, where he joined as a Government Affairs Director in the UK. He then took further roles of growing responsibilities in the Corporate Media and Global Public Health teams, where he leveraged GSK's leadership in Global Public Health to drive improved access to medicines and vaccines and to implement the introduction of world's first pneumococcal and rotavirus vaccines into sub-Saharan Africa. He also worked in the US for three years, leading Communications and Government Affairs for the US Pharmaceuticals business, as a member of the Executive Team.
In his previous role, Stephen led a global team for two years to drive the reputation of GSK's Consumer Healthcare business through the successful transition and on-boarding of the Consumer Healthcare CEO and driving the integration work following the Novartis deal.
Prior to joining GSK, he worked for Shell International, as well as for a communications consultancy, after three years as a journalist for the BBC. Stephen holds a postgraduate diploma in Broadcast Journalism from Cardiff University.
As the head of research and development for ViiV Healthcare, Dr. Kimberly Smith MD, MPH oversees the clinical development of our pipeline assets in support of our overall company strategy to deliver meaningful advances in treatment and care for people living with HIV.
Dr. Smith is a graduate of the University of Michigan School of Medicine and also holds a MPH degree from the University of Michigan School of Public Health. She completed her internship, residency, and Infectious Disease fellowship at Rush University Medical Centre in Chicago. Following her training she joined the faculty of the Section of Infectious Disease at Rush University Medical Center in Chicago.
Prior to joining ViiV Healthcare in late 2013, Dr. Smith served as the Principle Investigator of the Rush University Medical Center Clinical Research Site of the AIDS Clinical Trials Group (ACTG). Dr. Smith also served as the chair of the ACTG Underrepresented Populations committee and chair of multiple ACTG clinical trials. She has been a member of NIH study sections, the HIVMA Board of Directors, the CDC Board of Scientific Counselors and numerous advisory committees. Dr. Smith has published over 100 articles, abstracts and manuscripts and she co-edited one of the few books, HIV/AIDS in U.S. Communities of Color, which addressed the HIV epidemic among minorities in the US.
In addition to her research activities Dr. Smith has been an active HIV clinician, clinical educator, community leader and advocate. She has lectured at countless local national and international conferences including the Conference on Retroviruses and Opportunistic Infections (CROI), the International AIDS Conference, The International Conference on Antimicrobial Agents and Chemotherapy, and Infectious Disease Society of America.
Tim Tordoff is Senior Vice President & Head of Europe, having joined ViiV Healthcare from GSK in June 2013. He has overall accountability for the ViiV Healthcare business across Europe, which includes nine ViiV countries and 21 GSK Alliance markets. Tim joined GSK in 1993 and held senior roles within the respiratory organisation as Head of Global Commercial strategy and creating the Respiratory Centre of Excellence in Pharma Europe before being appointed General Manager, GSK Ireland in 2005. In this role, which included responsibility for the HIV business in the market, Tim drove a step change in government understanding and engagement with GSK. Following this, he was appointed Vice President Primary Care, and was instrumental in focusing the customer facing teams on launch and growth brands in a rapidly changing UK customer environment. This led to the successful launch of four medicines in 18-months. His last role in GSK before joining ViiV Healthcare was Vice President Service Development Core Business Services, during which he was able to create significant value for the GSK business through the establishment of a global network of Business Service Centres to deliver more customer focused services, leading Global Digital Services and setting up the Mergers, Acquisition and Divestment team.
Craig Williams is our Head of International since 1 September 2018.
Prior to his appointment in ViiV Healthcare, Craig held positions in the US, Europe and Emerging Markets for GSK. He demonstrated consistent success and learning agility, progressing from Sales Representative to VP, leading commercial operations in over 50 markets and across all GSK portfolios. During his career, Craig has been a part of successfully launching more than 15 new medicines in countries around the world.
Known for his engaging leadership style, Craig has played a huge role in supporting diversity inclusion and global development programmes for key talent.